1.
Antonova AU, Lonardi S, Monti M, et al. A distinct human cell type expressing MHCII and RORγt with dual characteristics of dendritic cells and type 3 innate lymphoid cells. Proceedings of the National Academy of Sciences of the United States of America. 2023;120(52):e2318710120. doi:10.1073/pnas.2318710120.
1.
Iorgulescu B, Braun D, Oliveira G, Keskin DB, Wu CJ. Acquired mechanisms of immune escape in cancer following immunotherapy. Genome Med. 2018;10(1):87. doi:10.1186/s13073-018-0598-2.
1.
Ito Y, Ashenberg O, Pyrdol J, et al. Rapid CLIP dissociation from MHC II promotes an unusual antigen presentation pathway in autoimmunity. J Exp Med. 2018;215(10):2617-2635. doi:10.1084/jem.20180300.
1.
Abelin JG, Keskin DB, Sarkizova S, et al. Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction. Immunity. 2017;46(2):315-326. doi:10.1016/j.immuni.2017.02.007.
1.
Villani A-C, Satija R, Reynolds G, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science. 2017;356(6335). doi:10.1126/science.aah4573.
1.
Manguso RT, Pope HW, Zimmer MD, et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017;547(7664):413-418. doi:10.1038/nature23270.
1.
Patel SJ, Sanjana NE, Kishton RJ, et al. Identification of essential genes for cancer immunotherapy. Nature. 2017;548(7669):537-542. doi:10.1038/nature23477.
1.
Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471-475. doi:10.1038/nature23465.
1.
Sade-Feldman M, Jiao YJ, Chen JH, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017;8(1):1136. doi:10.1038/s41467-017-01062-w.
1.
Vokes NI, Van Allen EM. Tumor Evolution: A Problem of Histocompatibility. Cell. 2017;171(6):1252-1253. doi:10.1016/j.cell.2017.11.012.